Monoclonal antibody therapy in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• The treatment of multiple myeloma (MM) has advanced significantly with proteasome inhibitors and immunomodulatory drugs.
• Previous use of monoclonal antibodies (mAbs) in MM treatment yielded disappointing results until recently.
• Novel targets in MM have led to the development and approval of effective mAb therapies.

Purpose of the Study:

• To review preclinical research and clinical trials of monoclonal antibodies targeting multiple myeloma.
• To identify novel targets and evaluate the efficacy of mAbs in MM treatment.

Main Methods:

• Conducted a literature search of peer-reviewed publications, congress abstracts, and clinical trial data (e.g., clinicaltrials.gov).
• Identified preclinical studies (in vitro and in vivo models) and clinical trials involving mAbs for MM.
• Analyzed data on various antibody formats, single-agent, and combination therapies.

Main Results:

• Several targets have been investigated in preclinical MM models.
• A growing number of mAbs are under evaluation in clinical trials for MM.
• Two mAbs, targeting CD38 and SLAMF7, have been approved for MM treatment.

Conclusions:

• The recent approval of CD38 and SLAMF7 targeting mAbs marks a significant advancement in MM therapy.
• These new antibodies are expected to profoundly influence treatment approaches and patient outcomes in MM.
• The impact will be seen in both transplant-eligible and elderly MM patient populations.